GoldenGolden
Agendia

Agendia

Agendia is an Irvine, California-based molecular diagnostics company.

Agendia’s genomic testing platforms help in matching each patient to the right treatment to help minimize under- and over-treatment, and improve their quality of life.

Timeline

July 2018
Agendia raises a $35,000,000 private equity from Athyrium Capital Management, LP.
July 2015
Agendia raises a $4,839,000 grant from EASME.
March 2014
Agendia raises a $18,145,710 venture round from Norgine Ventures.
September 23, 2009
Agendia raises a $23,000,000 series E round from Gilde Healthcare Partners and ING Group.
2008
Agendia was founded by PROF. DR. RENÉ BERNARDS, PhD and PROF. LAURA VAN ‘T VEER, PhD.
August 28, 2007
Agendia raises a $34,000,000 series D round from Gilde Healthcare Partners.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Conor Hale
June 7, 2021
FierceBiotech
New data on Agendia's MammaPrint test showed it could help identify patients at an ultra low risk of recurrence, including some who are likely to not see their tumor return for at least 20 years and could potentially skip chemotherapy--and the side effects that come with it.
Conor Hale
November 20, 2020
FierceBiotech
Breast cancer diagnostic developer Agendia announced plans to integrate its genomic tests with Paige's artificial-intelligence-powered pathology services with the goal of building a new digital precision oncology platform.
Alex Keown
May 8, 2020
BioSpace
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.